Nexium
Product Images NDC 54868-4510

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Nexium (NDC 54868-4510). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Nexium 40mg Label (4510)

NEXIUM 40 mg capsules packaging label from Physicians Total Care, Inc., containing 60 capsules. The label includes the active ingredient esomeprazole magnesium and cautions that federal law prohibits dispensing without a prescription. It provides storage instructions, usage directions, and batch information including lot number and expiration date.*

FDA Label Image

Nexium 20mg Label (4635)

NEXIUM 20MG packaging label distributed by Physicians Total Care, Inc. The label includes lot number 000 and an expiration date 01/60. Manufacturer information lists Astra Zeneca AB, S-17141 Sodertalje, Sweden. The label also features a barcode.*

FDA Label Image

Figure 1 (Chemiical Structure)

Chemical structure diagram of the active ingredient in NEXIUM, showing the molecular configuration including methoxy groups (OCH3), methyl groups (CH3), nitrogen atoms, a sulfoxide (SO) group, and bound magnesium ions with three water molecules (Mg2+ · 3 H2O).*

FDA Label Image

Figurefour (Nexiumpacket Figurefour)

A line graph showing the percent of patients symptom-free over a 28-day diary period for NEXIUM 40 mg, NEXIUM 20 mg, and placebo groups. The vertical axis represents the percent of patients symptom-free, and the horizontal axis represents diary days. The graph compares symptom relief progression across the three groups over time.*

FDA Label Image

Figureone (Nexiumpacket Figureone)

A line graph depicting the percent maintained over months for NEXIUM at doses of 40 mg, 20 mg, and 10 mg, compared to placebo. The vertical axis shows percent maintained from 0 to 100, and the horizontal axis shows time in months from 0 to 6. Lines represent patient counts for each group: 40 mg (N=92), 20 mg (N=96), 10 mg (N=91), and placebo (N=94).*

FDA Label Image

Figurethree (Nexiumpacket Figurethree)

A line graph comparing the percent of patients symptom-free over 28 days for NEXIUM 40 mg, NEXIUM 20 mg, and placebo. The x-axis represents diary day from 0 to 28, and the y-axis shows the percent of patients symptom-free from 0 to 100%. Three lines illustrate patient symptom-free percentages for each treatment group across the study period.*

FDA Label Image

Figuretwo (Nexiumpacket Figuretwo)

A line graph depicting the percentage of subjects maintaining a condition over six months for NEXIUM at 10 mg, 20 mg, and 40 mg doses compared to placebo. The vertical axis shows percent maintained from 0 to 100, and the horizontal axis represents time in months from baseline to six months. Data points indicate higher maintenance percentages for NEXIUM doses than placebo over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.